Neurophet, an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced a ...

Under the terms of this agreement, the aggregated potential transaction value, including development, commercial, regulatory ...

Laboratoires Pierre Fabre Singapore is delighted to announce the access for patients to BRAFTOVI® (encorafenib) in ...

Lonza acquires five CDMO manufacturing sites and approximately 1,100 highly skilled employees, more than doubling its US ...

Farrer Park Hospital (FPH) announced the introduction of the Edge® Multi-Port Endoscopic Surgical Robot (MP1000) in Singapore ...

JH2-selective TYK2 inhibitor meets primary and key secondary endpoints, with over 80% of patients achieving clear or almost ...

The commercial list moved the other way. Sixty-two products applied and 58 passed formal review. In 2025 the same stage had ...

In October 2026, Nuance Pharma announces the first patient dosed in the REACH Phase III trial, a randomized, double-blind, ...

Shanghai Zhimeng Biopharma, Inc. ( "Zhimeng Biopharma") announced that its independently developed next-generation potassium channel opener, CB03-154, intended for the treatment of amyotrophic lateral ...

Lynk Pharmaceuticals Expands Simcere Partnership to Commercialise Zemprocitinib for Atopic Dermatitis in Greater China ...

Over 70% of patients achieved PASI 90 and more than 80% reached PGA 0/1 at Week 16, demonstrating significant efficacy over placebo with no new safety signals.

Backed by GSK, Pfizer and Sanofi, the Cascade initiative will integrate single-cell sequencing and protein data to strengthen predictive models of human immune responses.